Positron emission tomography imaging of tumor hypoxia

Current Medical Imaging Reviews

Volumn 6, Issue 1, 2010, Pages 8-16

  Fang, Shengwei ^a,b,c   Tian, Mei ^d   Zhang, Hong ^a,b,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c Key Laboratory of Medical Molecular Imaging of Zhejiang Province   (China)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Cu ATSM; Hypoxia imaging; Molecular imaging; Nitroimidazole; Positron Emission Tomography (PET); Tumor hypoxia

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; BIOLOGICAL MARKER; FLUOROALKYL ACETAMIDE; FLUOROAZOMYCIN ARABINOSIDE F 18; FLUOROERYTHRONITROIMIDAZOLE; FLUOROETANIDAZOLE F 18; IODOAZOMYCIN ARABINOSIDE IODINE 124; NITROIMIDAZOLE DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

ADVANCED CANCER; AUTORADIOGRAPHY; CELL HYPOXIA; CELL SURVIVAL; COMPARATIVE STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG UPTAKE; GLIOMA; HEAD AND NECK CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE PROCEDURE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; METASTASIS; MOLECULAR IMAGING; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; OPTICAL RESOLUTION; PATIENT IDENTIFICATION; POSITRON EMISSION TOMOGRAPHY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS; REVIEW; SQUAMOUS CELL CARCINOMA; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TUMOR CELL; TUMOR VASCULARIZATION; UPREGULATION;

EID: 77950237629     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340510790693910     Document Type: Review

References (115)

1. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
2. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004; 9(5): 4-9.
3. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9: 539-549
4. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732
5. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 1995; 92: 5510-5514
6. Hon WC, Wilson MI, Harlos K, et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature 2002; 417: 975-978
7. Yamashita K, Discher DJ, Hu J, Bishopric NH, Webster KA. Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, AND p300/CBP. J Biol Chem 2001; 276: 12645-12653
8. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006; 70: 1469-1480
9. Wykoff CC, Beasley N, Watson PH, et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 2001; 158: 1011-1019
10. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 7075-7083
11. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001; 276: 9519-9525
12. Richardson SM, Knowles R, Tyler J, Mobasheri A, Hoyland JA. Expression of glucose transporters GLUT-1, GLUT-3, GLUT-9 and HIF-1alpha in normal and degenerate human intervertebral disc. Histochem Cell Biol 2008; 129: 503-511
13. Shackelford DB, Vasquez DS, Corbeil J, et al. mTOR and HIF- 1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci USA 2009; 106: 11137-11142
14. Luo F, Liu X, Yan N, et al. Hypoxia-inducible transcription factor- 1alpha promotes hypoxia-induced A549 apoptosis via a mechanism that involves the glycolysis pathway. BMC Cancer 2006; 6: 26.
15. Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 2007; 13: 5670-5674
16. Said HM, Hagemann C, Staab A, et al. Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. Radiother Oncol 2007; 83: 398-405.
17. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996; 6: 10-21.
18. Snyder SA, Dewhirst MW, Hauck ML. The role of hypoxia in canine cancer. Vet Comp Oncol 2008; 6: 213-223
19. Takeshita M, Grollman AP, Ohtsubo E, Ohtsubo H. Interaction of bleomycin with DNA. Proc Natl Acad Sci USA 1978; 75: 5983-5987
20. Seifried HE, Anderson DE, Fisher EI, Milner JA. A review of the interaction among dietary antioxidants and reactive oxygen species. J Nutr Biochem 2007; 18: 567-579
21. Koch S, Mayer F, Honecker F, Schittenhelm M, Bokemeyer C. Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. Br J Cancer 2003; 89: 2133-2139
22. Hussein D, Estlin EJ, Dive C, Makin GW. Chronic hypoxia promotes hypoxia-inducible factor-1alpha-dependent resistance to etoposide and vincristine in neuroblastoma cells. Mol Cancer Ther 2006; 5: 2241-2250
23. Sanna K, Rofstad EK. Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer 1994; 58: 258-262
24. Song X, Liu X, Chi W, et al. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer Chemother Pharmacol 2006; 58: 776-784
25. 2 tension measurements. Cancer Res 1991; 51: 6098-6102
26. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001; 28: 29-35.
27. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008; 49(2) :129S-48S.
28. Mueller-Klieser W, Schlenger KH, Walenta S, et al. Pathophysiological approaches to identifying tumor hypoxia in patients. Radiother Oncol 1991; 20 (1): 21-28
29. 2 tension measurements. Cancer Res 1991; 51: 3316-3322
30. Menon C, Fraker DL. Tumor oxygenation status as a prognostic marker. Cancer Lett 2005; 221: 225-235
31. Nozue M, Lee I, Yuan F, et al. Interlaboratory variation in oxygen tension measurement by Eppendorf "Histograph" and comparison with hypoxic marker. J Surg Oncol 1997; 66: 30-38
32. Joseph GR, Kenneth AK. PET imaging for tumor hypoxia: characterizing the tumor and guiding treatment. London: Springer; 2006.
33. Beziat F, Touraille S, Debise R, et al. Biochemical and molecular consequences of massive mitochondrial gene loss in different tissues of a mutant strain of Drosophila subobscura. J Biol Chem 1997; 272: 22583-22590
34. Wang W, Georgi JC, Nehmeh SA, et al. Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging. Phys Med Biol 2009; 54: 3083-3099
35. Zhang H, Zheng X, Yang X, et al. 11C-NMSP/ 18F-FDG microPET to monitor neural stem cell transplantation in a rat model of traumatic brain injury. Eur J Nucl Med Mol Imaging 2008; 35: 1699-1708
36. Dische S, Saunders MI, Anderson P, Stratford MR, Minchinton A. Clinical experience with nitroimidazoles as radiosensitizers. Int J Radiat Oncol Biol Phys 1982; 8: 335-338
37. Mees G, Dierckx R, Vangestel C, Van de Wiele C. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 2009; 36: 1674-1686
38. Prekeges JL, Rasey JS, Grunbaum Z, Krohn KH. Reduction of fluoromisonidazole, a new imaging agent for hypoxia. Biochem Pharmacol 1991; 42: 2387-2395
39. Eschmann SM, Paulsen F, Reimold M, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005; 46: 253-260
40. 2 electrode measurements. Influence of tumour volume and carbogen breathing. Acta Oncol 2002; 41: 304-312
41. Kubota K, Tada M, Yamada S, et al. Comparison of the distribution of fluorine-18 fluoromisonidazole, deoxyglucose and methionine in tumour tissue. Eur J Nucl Med 1999; 26: 750-757
42. 2 measurements in murine tumors. Int J Radiat Oncol Biol Phys 2005; 62: 854-861
43. Troost EG, Laverman P, Kaanders JH, et al. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol 2006; 80: 157-164
44. Dubois L, Landuyt W, Haustermans K, et al. Evaluation of hypoxia in an experimental rat tumour model by [(18)F]fluoromisonidazole PET and immunohistochemistry. Br J Cancer 2004; 91: 1947-1954.
45. Troost EG, Laverman P, Philippens ME, et al. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 2008; 35: 1803-1811
46. Lehmann S, Stiehl DP, Honer M, et al. Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events. Proc Natl Acad Sci USA 2009; 106: 14004-14009
47. Rasey JS, Koh WJ, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36: 417-428
48. 2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 2006; 33: 1426-1431
49. Gagel B, Piroth M, Pinkawa M, et al. pO polarography, contrast enhanced color duplex sonography (CDS), [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer 2007; 7: 113.
50. Lawrentschuk N, Poon AM, Foo SS, et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int 2005; 96: 540-546
51. Bentzen L, Keiding S, Nordsmark M, et al. Tumour oxygenation assessed by 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 2003; 67: 339-344
52. Cher LM, Murone C, Lawrentschuk N, et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 2006; 47: 410-418
53. Cherk MH, Foo SS, Poon AM, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET. J Nucl Med 2006; 47: 1921-1926
54. Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 2006; 80: 151-156
55. Rajendran JG, Mankoff DA, O'Sullivan F, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004; 10: 2245-2252
56. Rajendran JG, Schwartz DL, O'Sullivan J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006; 12: 5435-5441
57. Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 2005; 32: 1384-1391
58. Gagel B, Reinartz P, Demirel C, et al. [18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 2006; 6: 51.
59. Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 2008; 35: 2294-2303
60. Piert M, Machulla HJ, Picchio M, et al. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005; 46: 106-113
61. 2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys 2008; 70: 1202-1212
62. Souvatzoglou M, Grosu AL, Roper B, et al. Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging 2007; 34: 1566-1575
63. Reischl G, Dorow DS, Cullinane C, et al. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA-first small animal PET results. J Pharm Pharm Sci 2007; 10: 203-211
64. Beck R, Roper B, Carlsen JM, et al. Pretreatment 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med 2007; 48: 973-980
65. Grosu AL, Souvatzoglou M, Roper B, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007; 69: 541-551
66. Postema EJ, McEwan AJ, Riauka TA, et al. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabinofuranosyl)-2- nitroimidazole ( 18F-FAZA). Eur J Nucl Med Mol Imaging 2009; 36: 1565-1573
67. Parliament MB, Chapman JD, Urtasun RC, et al. Non-invasive assessment of human tumour hypoxia with 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br J Cancer 1992; 65: 90-95
68. Mannan RH, Somayaji VV, Lee J, Mercer JR, Chapman JD, Wiebe LI. Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl)-2-nitroimidazole (iodoazomycin arabinoside: IAZA): a novel marker of tissue hypoxia. J Nucl Med 1991; 32:1764-1770
69. Stypinski D, McQuarrie SA, Wiebe LI, Tam YK, Mercer JR, McEwan AJ. Dosimetry estimations for 123I-IAZA in healthy volunteers. J Nucl Med 2001; 42: 1418-1423
70. Kumar P, McQuarrie SA, Zhou A, McEwan AJ, Wiebe LI. [131I] Iodoazomycin arabinoside for low-dose-rate isotope radiotherapy: radiolabeling, stability, long-term whole-body clearance and radiation dosimetry estimates in mice. Nucl Med Biol 2005; 32: 647-653
71. Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995; 194: 795-800.
72. Tolvanen T, Lehtio K, Kulmala J, et al. 18FFluoroerythronitroimidazole radiation dosimetry in cancer studies. J Nucl Med 2002; 43: 1674-1680
73. Gronroos T, Eskola O, Lehtio K, et al. Pharmacokinetics of [18F]FETNIM: a potential marker for PET. J Nucl Med 2001; 42: 1397-1404
74. Gronroos T, Bentzen L, Marjamaki P, et al. Comparison of the biodistribution of two hypoxia markers [18F]FETNIM and [18F]FMISO in an experimental mammary carcinoma. Eur J Nucl Med Mol Imaging 2004; 31: 513-520
75. Lehtio K, Oikonen V, Nyman S, et al. Quantifying tumour hypoxia with fluorine-18 fluoroerythronitroimidazole ([18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging 2003; 30: 101-108
76. Lehtio K, Eskola O, Viljanen T, et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-andneck cancer. Int J Radiat Oncol Biol Phys 2004; 59: 971-982
77. Tewson TJ. Synthesis of [18F]fluoroetanidazole: a potential new tracer for imaging hypoxia. Nucl Med Biol 1997; 24: 755-760
78. Rasey JS, Hofstrand PD, Chin LK, Tewson TJ. Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 1999; 40: 1072-1079
79. Evans SM, Joiner B, Jenkins WT, Laughlin KM, Lord EM, Koch CJ. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br J Cancer 1995; 72: 875-882
80. Allemann K, Wyss MT, Wergin M, et al. Measurements of hypoxia ([(18)F]-FMISO, [(18)F]-EF5) with positron emission tomography (PET) and perfusion using PET ([(15)O]-H(2)O) and power Doppler ultrasonography in feline fibrosarcomas*. Vet Comp Oncol 2005; 3: 211-221
81. Kachur AV, Dolbier WR, Jr., Evans SM, et al. Synthesis of new hypoxia markers EF1 and [18F]-EF1. Appl Radiat Isot 1999; 51: 643-650
82. Evans SM, Kachur AV, Shiue CY, et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 2000; 41: 327-336
83. Josse O, Labar D, Georges B, Gregoire V, Marchand-Brynaert J. Synthesis of [18F]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)- acetamide], a marker for PET detection of hypoxia. Bioorg Med Chem 2001; 9: 665-675
84. Mahy P, De Bast M, Leveque PH, et al. Preclinical validation of the hypoxia tracer 2-(2-nitroimidazol-1-yl)- N-(3,3,3-[(18)F]trifluoropropyl) acetamide, [(18)F]EF3. Eur J Nucl Med Mol Imaging 2004; 31: 1263-1272
85. Mahy P, De Bast M, Gillart J, Labar D, Gregoire V. Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis. Eur J Nucl Med Mol Imaging 2006; 33: 553-556
86. Mahy P, De Bast M, de Groot T, et al. Comparative pharmacokinetics, biodistribution, metabolism and hypoxiadependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models. Radiother Oncol 2008; 89: 353-360
87. Dubois L, Landuyt W, Cloetens L, et al. [18F]EF3 is not superior to [18F]FMISO for PET-based hypoxia evaluation as measured in a rat rhabdomyosarcoma tumour model. Eur J Nucl Med Mol Imaging 2009; 36: 209-218
88. Christian N, Bol A, De Bast M, et al. Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model. Eur J Nucl Med Mol Imaging 2007; 34: 1348-1354
89. Dolbier WR, Jr., Li AR, Koch CJ, Shiue CY, Kachur AV. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 2001; 54: 73-80.
90. Ziemer LS, Evans SM, Kachur AV, et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med Mol Imaging 2003; 30: 259-266
91. Yapp DT, Woo J, Kartono A, et al. Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F-EF5 and positron emission tomography. BJU Int 2007; 99: 1154-1160
92. Mahy P, Geets X, Lonneux M, et al. Determination of tumour hypoxia with [18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism. Eur J Nucl Med Mol Imaging 2008; 35: 1282-1289
93. Komar G, Seppanen M, Eskola O, et al. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med 2008; 49: 1944-1951
94. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997; 38: 1155-1160
95. Obata A, Yoshimi E, Waki A, et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cudiacetyl- bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med 2001; 15: 499-504.
96. Wood KA, Wong WL, Saunders MI. [(64)Cu]diacetyl-bis(N(4)-methyl- thiosemicarbazone) - a radiotracer for tumor hypoxia. Nucl Med Biol 2008; 35: 393-400.
97. Holland JP, Lewis JS, Dehdashti F. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q J Nucl Med Mol Imaging. 2009; 53: 193-200.
98. Dearling JL, Lewis JS, Mullen GE, Rae MT, Zweit J, Blower PJ. Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. Eur J Nucl Med 1998; 25: 788-792
99. Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 1999; 40: 177-183
100. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med 2001; 42: 655-661
101. 2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005; 61: 1493-1502
102. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2006; 47: 989-998
103. Tanaka T, Furukawa T, Fujieda S, Kasamatsu S, Yonekura Y, Fujibayashi Y. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nucl Med Biol 2006; 33: 743-750
104. Oh M, Tanaka T, Kobayashi M, et al. Radio-copper-labeled Cu- ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model. Nucl Med Biol 2009; 36: 419-426
105. Lewis J, Laforest R, Buettner T, et al. Copper-64-diacetyl-bis(N4- methylthiosemicarbazone): An agent for radiotherapy. Proc Natl Acad Sci USA 2001; 98: 1206-1211
106. Weeks AJ, Paul RL, Marsden PK, Blower PJ, Lloyd DR. Radiobiological effects of hypoxia-dependent uptake of (64)Cu-ATSM: enhanced DNA damage and cytotoxicity in hypoxic cells. Eur J Nucl Med Mol Imaging 2009. Epub ahead of print.
107. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys 2003; 55: 1233-1238
108. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003; 30: 844-850
109. Dietz DW, Dehdashti F, Grigsby PW, et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 2008; 51: 1641-1648
110. Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 2008; 49: 1177-1182
111. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008; 49: 201-205
112. Grigsby PW, Malyapa RS, Higashikubo R, et al. Comparison of molecular markers of hypoxia and imaging with (60)Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol 2007; 9: 278-283
113. Chao KS, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001; 49: 1171-1182
114. Bowen SR, Flynn RT, Bentzen SM, Jeraj R. On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. Phys Med Biol 2009; 54: 1483-1501
115. Flynn RT, Bowen SR, Bentzen SM, Rockwell Mackie T, Jeraj R. Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Phys Med Biol 2008; 53: 4153-4167